Alkem launches probiotic “DSS” in India for gut health management
Alkem Laboratories launches DSS probiotic in India for gut health, a strategic addition to their gastrointestinal portfolio. CEO emphasizes commitment to innovative health solutions.
The launch of a new product in a growing market segment is likely to have a moderate positive impact on the company's business.
The press release announces a new product launch with positive statements from the CEO and highlights the growing market for probiotics.
* Alkem Laboratories Ltd has launched probiotic “DSS”, the original De Simone formulation, in India for gut health management. * DSS is developed by Prof. Claudio De Simone, combining eight bacterial strains. * It's backed by over 80 clinical trials and 200 publications. * Alkem has in-licensed these formulations from Next Gen Pharma India Pvt. Ltd. * Alkem’s DSS range will be available in four strengths: 225 billion CFU sachet, 112.5 billion CFU capsule, 45 billion CFU capsule, and 10 billion CFU capsule. * Alkem is the first company offering all four strengths of this probiotic in India and also the first to launch 225 billion CFU and 10 billion CFU strengths in India. * DSS is indicated for the management of various disorders such as Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC), Pouchitis, Hepatic Encephalopathy (HE), Non -Alcoholic Fatty Liver Disease (NAFLD) , Cirrhosis , Bacterial Vaginosis (BV), Antibiotic -Associated Diarrhea (AAD) , and other gut dysbiosis -related conditions , as well as for supplementation during pregnancy and lactation. * According to IQVIA data (MAT October 2025), the prescription probiotic market in India is valued at around ₹2,071 crore, and has recorded a five -year CAGR of approximately 14%. * Dr. Vikas Gupta, Chief Executive Officer, Alkem, said, “There is a growing focus on managing gut health as an integral part of overall well -being, and probiotics have emerged as a key enabler in this space. The launch of DSS , a globally -trusted, high -potent, multi -strain probiotic, is a strategic addition to our comprehensive product portfolio in the gastrointestinal segment, and underscores our commitment to making innovative and evidence -based health solutions accessible to Indian patients.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under product launches. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.